IMR Press / EJGO / Volume 38 / Issue 6 / DOI: 10.12892/ejgo3685.2017
Open Access Original Research
Concurrent external beam pelvic radiotherapy and weekly paclitaxel/carboplatin therapy followed by hysterectomy improves prognosis and survival of patients with non-squamous cell carcinoma of the cervix
Show Less
1 Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan
2 Department of Gynecology, Kyosai Hospital, Saitama, Japan
Eur. J. Gynaecol. Oncol. 2017 , 38(6), 860–866; https://doi.org/10.12892/ejgo3685.2017
Published: 10 December 2017
Abstract

Purpose of investigation: The authors determined whether concurrent chemoradiotherapy (CCRT) followed by hysterectomy improves progression-free survival (PFS) and overall survival (OS) in patients with squamous cell carcinoma (SCC) and non–SCC of the cervix. Materials and Methods: The authors retrospectively reviewed records of 110 cervical cancer patients (FIGO Stages IB2-IVB) who underwent CCRT with paclitaxel/carboplatin. Extrafascial hysterectomy was performed for local control; primary outcomes included PFS and OS. Results: The sample comprising 80% SCC, 15.5% adenocarcinoma, and 4.5% other types of carcinoma patients was followed for 45.0 ± 21.0 months. The three-year PFS and OS rates were 68% vs. 65% (p = 0.76), and 88% vs. 72% (p = 0.26) for all patients with and without hysterectomy, respectively. The three-year PFS and OS rates were 64% vs. 38% (p = 0.32), and 85% vs. 38% (p = 0.025) for non-SCC patients with and without hysterectomy, respectively. Conclusions: Hysterectomy after CCRT with paclitaxel/ carboplatin improves prognosis in patients with non-SCC of the cervix.
Keywords
Cervical neoplasms
Concurrent chemoradiotherapy
Paclitaxel
Carboplatin
Survival
Hysterectomy
Surgery
Share
Back to top